Register now and save 10% on Understanding Ketamine and Psychedelic Integration workshops this spring and fall! Use coupon code HEAL2021 at checkout.*
*Now through April 1 at midnight PST. Discount applies to workshops May-October 2021; does not apply to CE or CME.

Integrating Psychedelics with Evidence-Based Therapy, Fall 2021 | Online

This 12-week course will focus on the use of evidence-based therapies in psychedelic therapies.

RegisterApply NowCourse FullCourse Full

Event details

Integrating Psychedelics with Evidence-Based Therapy


Alan K. Davis, PhD, Fluence Lead Trainer


Thursdays, 5:30-7 PM Eastern Time (EDT through November 6th/EST starting November 7th) from September 2nd to November 18th




$1,200 for 12-sessions

Optional CE certificate for $65

To obtain your certificate, the CE form must be filled out within 14 days of class completion.

A limited number of Diversity Fund scholarships are available, please complete this application.

Certificate Program

This course can be taken in partial fulfillment of the requirements for the Fluence Postgraduate Certificate in Psychedelic Integration Therapy or Ketamine-assisted Psychotherapy.

Course Description

This reading and study group will maintain the same membership for the 12-week period. The group will have a syllabus with readings that participants will be expected to read prior to each discussion group meeting. The format for each session will include a short review of each paper by the group leader, followed by a discussion of the content and group members’ perspectives of the topic. This is an active group and weekly participation is required. The group is ideal for clinicians, graduate students, researchers, or the public, so long as they have training or interest in the scientific understanding of evidenced-based clinical interventions and their integration in psychedelic therapy. Readings will primarily include papers in the academic literature. Topics will include coverage of several different evidenced-based therapies (e.g., ACT, MI, CBT, PE, DBT), several types of psychedelics (e.g., psilocybin, ayahuasca, MDMA, ibogaine), and a variety of clinical populations (e.g., depression, social anxiety, addiction).

Weekly topics/readings:

Week 1: Hallucinogensin mental health treatment & Safety and ethical concerns
Week 2: Psychedelics and music
Week 3: Race as a component of set and setting & Ketamine-assisted therapyfor racial trauma
Week 4: Psilocybin therapy with ACT
Week 5: Psilocybin for depression
Week 6: Psilocybin for long-term AIDS survivors
Week 7: Psilocybin for tobacco addiction: Qualitative Mechanisms
Week 8: MDMA for PTSD Phase III
Week 9: MDMA therapy for PTSD with couples
Week 10: MDMA for autistic adults
Week 11: LSD therapy for anxiety related to life-threatening illness
Week 12: Predicting Psychedelic Drug Effects

Learning Objectives:  
At the end of the group, the participant will be able to:

1. Describe a variety of evidenced-based interventions that have been integrated into psychedelic-assisted psychotherapy studies
2. Explain the role of psychotherapy in psychedelic treatment across a variety of clinical populations
3. Critique the use of specific evidenced-based treatments as opposed to a supportive psychotherapeutic approach
4. Explain the role of psychological flexibility and how this may be a trans-diagnostic feature of evidenced-based interventions within the context of psychedelic therapy.
5. Describe the ethical concerns related to the provision of evidenced-based interventions within psychedelic therapy
6. List the basic components of psychedelic therapy
7. Describe the ways in which the acute effects of psychedelics are related to psychotherapeutic processes
8. Explain the safety concerns related to psychedelic therapy
9. Compare the different approaches to psychedelic therapy and evidenced-based interventions
10. Explain the history of psychedelic therapy leading up to current trials
11. Describe the basic pharmacology of psychedelic drugs
12. List the features of the psychotherapeutic relationship that are critical to psychedelic interventions
13. Explain the role of psychotherapy in psychedelic treatment across a variety of clinical populations


Information on Continuing Education Credit for Health Professionals (CE)

At this time Fluence is not able to offer CE for NY-state Psychologists or NY-state Social Workers for this course

  • CE credits for psychologists are provided by the Spiritual Competency Academy (SCA) which is co-sponsoring this program. The Spiritual Competency Resource Center is approved by the American Psychological Association to sponsor continuing education for psychologists. The Spiritual Competency Resource Center maintains responsibility for this program and its content.
  • The California Board of Behavioral Sciences accepts CE credits for LCSW, LPCC, LEP, and LMFT license renewal for programs offered by approved sponsors of CE by the American Psychological Association.
  • LCSWs, MFTs, and other mental health professionals from states other than California need to check with their state licensing board as to whether or not they accept programs offered by approved sponsors of CE by the American Psychological Association.
  • SCA is approved by the California Board of Registered Nursing (BRN Provider CEP16887) for licensed nurses in California.
  • SCA is an approved CE provider for National Board Certified Health and Wellness Coaches (CEP Number 100196)
  • For questions about receiving your Certificate of Attendance, contact David Gumpel, For questions about CE, visit or contact David Lukoff, PhD at